U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT06905873) titled 'A Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-segmental Vitiligo' on March 11.
Brief Summary: A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.
Study Start Date: March 25
Study Type: INTERVENTIONAL
Condition:
Vitiligo
Intervention:
DRUG: FB102
Route of administration- Intravenous (IV)
DRUG: Placebo
Route of administration- Intravenous (IV)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Forte Biosciences, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....